Sara Coca Membribes· @scocmem · X·· 1 day agoScore70
Body · original
#ESMO26 Long-term EV-103 follow-up (up to 7 years) shows remarkable durability with ~30% of responders still in response at 7 years
The next step is identifying long-term responders through biomarkers (Nectin4?) and optimising treatment duration (ctDNA?)
@OncoAlert
224 views · 6 likes · 5 reposts · 0 replies
Conference abstracts
4740ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial
Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
https://esmocongress.esmo.orgSource: Sara Coca Membribes · x.com